Genasense CLL Trial Meets Primary Endpoint, But Survival Benefit Not Yet Shown
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta believes that the lack of a survival benefit seen in a Phase III trial of Genasense in chronic lymphocytic leukemia reflects the relatively short follow-up time available for analysis, CEO Raymond Warrell said during a Nov. 9 earnings call
You may also be interested in...
Genta's Genasense Rolling NDA For Chronic Leukemia To Wrap In Fourth Quarter
The company has requested an FDA meeting to discuss a confirmatory Phase IV study protocol.
Genta's Genasense Rolling NDA For Chronic Leukemia To Wrap In Fourth Quarter
The company has requested an FDA meeting to discuss a confirmatory Phase IV study protocol.
Sanofi-Aventis Drops Genasense After Genta Declines To Modify Deal
Genta says it was approached by Aventis “on several occasions” after a negative Oncologic Drugs Advisory Committee review in May about modifying the financial terms of the oblimersen collaboration, “but we declined to make those accommodations.”